CRISPR Therapeutics

From Wikipedia, the free encyclopedia

CRISPR Therapeutics
TypePublic company
Nasdaq: CRSP
ISINCH0334081137
IndustryBiotechnology
Founded2013
FounderEmmanuelle Charpentier, Shaun Foy and Rodger Novak
HeadquartersZug, Switzerland
Key people
Samarth Kulkarni
(CEO)
RevenueUS$289.59 million (2019)
US$46.74 million (2019)
US$46.74 million (2019)
Total assetsUS$1.067 billion (2019)
Number of employees
304 (2019)
Websitewww.crisprtx.com

CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug. In fiscal year 2019, the company had revenues of $289.59 million, with net income of $66.86 million. In the same year, the number of employees stood at 304.[1] As of early 2021, the company had a market capitalization of over $13 billion.[2] CRISPR Therapeutics' investors include German chemical company Bayer. The company operates R&D in Cambridge, Massachusetts.[3]

History[]

CRISPR Therapeutics was founded in 2012. One of the co-founders Emmanuelle Charpentier later shared the Nobel Prize in Chemistry in 2020 with Jennifer Doudna. As part of a working group, she provided the first scientific documentation on the development and use of CRISPR gene editing. This allows DNA to be specifically modified and exchanged, which can for example prevent diseases. The company CRISPR Therapeutics is to apply this new technology commercially and advance research.[4]

In 2016, the company went public on NASDAQ.[5] In August 2016 the company started to operate Casebia Therapeutics, as a joint venture with Bayer. In 2019, Casebia Therapeutics came directly under the control of CRISPR Therapeutics.[6]

Products[]

The company has several drugs in development. These include the drug CTX001 for the treatment of the rare blood disorders Beta thalassemia and sickle cell disease, which is being developed jointly with Vertex Pharmaceuticals.[4] In May 2020, CTX001 received Orphan drug Designation from the U.S. Food and Drug Administration for transfusion-dependent beta thalassemia and from the European Medicines Agency for sickle cell disease and transfusion-dependent beta thalassemia.[7] Early clinical trial results support the safety and efficacy of this treatment.[8][9][10]

See also[]

References[]

  1. ^ "CRISPR THERAPEUTICS Bilanz GuV | Kennzahlen | Umsatz | Gewinn". finanzen.net (in German). Retrieved 8 January 2021.
  2. ^ "CRISPR Therapeutics AG (CRSP) Stock Price, News, Quote & History – Yahoo Finance". finance.yahoo.com. Retrieved 8 January 2021.
  3. ^ "Mission". CRISPR. Retrieved 15 April 2021.
  4. ^ Jump up to: a b "CRISPR Therapeutics: Ist diese Aktie nobelpreiswürdig?". GodmodeTrader (in German). Retrieved 8 January 2021.
  5. ^ "Börsengang von CRISPR Therapeutics an der NASDAQ". VISCHER (in German). Retrieved 8 January 2021.
  6. ^ "Bayer backs off running Casebia JV as CRISPR Tx takes over management". FierceBiotech. Retrieved 8 January 2021.
  7. ^ CRISPR Therapeutics and Vertex Pharmaceuticals Announce FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX001™ for the Treatment of Severe Hemoglobinopathies, PM Vertex 11 May 2020; retrieved 11 May 2020
  8. ^ Frangoul, Haydar; Altshuler, David; Cappellini, M. Domenica; Chen, Yi-Shan; Domm, Jennifer; Eustace, Brenda K.; Foell, Juergen; de la Fuente, Josu; Grupp, Stephan; Handgretinger, Rupert; Ho, Tony W. (21 January 2021). "CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia". New England Journal of Medicine. 384 (3): 252–260. doi:10.1056/NEJMoa2031054. ISSN 0028-4793. PMID 33283989.
  9. ^ "Synthego | Full Stack Genome Engineering". www.synthego.com. Retrieved 21 February 2021.
  10. ^ "1st Patients To Get CRISPR Gene-Editing Treatment Continue To Thrive". NPR.org. Retrieved 21 February 2021.
Retrieved from ""